advertisement
Abstract #3567 Published in IGR 4-2
Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a three-year follow-up: experience and incidence of side effects in a prospective study on 76 patients
Costagliola C; Del Prete A; Verolino M; Antinozzi P; Fusco R; Parmeggiani F; Mastropasqua LGraefe's Archive for Clinical and Experimental Ophthalmology 2002; 240: 379-386
PURPOSE: To assess the efficacy and side-effects of 0.005% latanoprost once daily during three years of treatment in glaucomatous patients in whom intraocular pressure (IOP) was not adequately controlled by beta-blockers twice daily. METHODS: An unmasked prospective study was performed on 76 glaucomatous patients (145 eyes) treated with 0.005% latanoprost at bedtime, after a 21-day wash-out period from beta-blockers. IOP measurement and visual field examination were recorded over the follow-up period. RESULTS: Latanoprost significantly reduced IOP from 26.5 ± 6.6 mmHg (mean ± SD) to 17.4 ± 2.7 mmHg after 36 months of treatment in 48 patients (63.1%), who completed the trial. Twenty-eight patients (36.8%) discontinued the therapy. In 12 patients (15.8%), the treatment did not obtain a satisfactory target IOP. In two subjects (2.6%), despite the IOP reduction, visual field damage progressed. The remaining ten patients (13.1%) discontinued the treatment because of the following side-effects: microfollicular conjunctivitis (seven cases); severe oedema of conjunctiva and eyelids (one case); corneal punctate erosion (one case); cystoid macular edema (one case). No flare or pigmentary changes of iris and eyelash were observed. CONCLUSIONS: Latanoprost 0.005% once daily significantly reduces IOP in the majority of glaucomatous patients uncontrolled by beta-blockers. The reduction of IOP was statistically significant during three years of follow-up, confirming the clinical efficacy of this compound. The ocular side-effects requiring cessation of therapy were mainly allergic reactions. The most severe adverse effects were one case of corneal punctate erosion and one case of cystoid macular edema in a pseudophakic patient.
Dr. C. Costagliola, Eye Clinic, University of Ferrara, Italy. sbd@dns.unife.it
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)